Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MTRAC Additional Review - March 2014

MTRAC issued an additional Commissioning Support review in March 2014. This review covers fluticasoe/vilanterol dry powder inhaler.

The fluticasoe/vilanterol (Relvar®) summary advises that this inhaler cannot be recommended for prescribing for the treatment of chronic obstructive pulmonary disease (COPD). It is noted that the evidence for efficacy was considered relatively weak although strong enough to gain regulatory approval. The main reason for this recommendation is a potential safety concern regarding the similarity of this inhaler to reliever inhalers in terms of colour that could result in accidental overuse of the inhaled steroid. The SPC describes the inhaler as having a "light grey body, a pale blue mouthpiece cover and a dose counter". Until now, blue coloured inhalers have generally contained short-acting beta-adrenoceptor agonists (SABA), not inhaled corticosteroids and long-acting beta-adrenoceptor agonists.

Action: Clinicians should be aware of these reviews and use the recommendations to guide appropriate use of these medicines in current practice.

Share 'MTRAC Additional Review - March 2014' on Email Share 'MTRAC Additional Review - March 2014' on Delicious Share 'MTRAC Additional Review - March 2014' on Digg Share 'MTRAC Additional Review - March 2014' on Facebook Share 'MTRAC Additional Review - March 2014' on Google+ Share 'MTRAC Additional Review - March 2014' on reddit Share 'MTRAC Additional Review - March 2014' on StumbleUpon Share 'MTRAC Additional Review - March 2014' on Twitter

atomic-wealth

No Comments to “MTRAC Additional Review - March 2014”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,665 spam comments.

atomic-wealth
fond-illness
summer